Cambridge University Press



Supplementary Material 3Literature Search and Preliminary ResultsWe used several strategies to identify eligible peer-reviewed literature. First, we identified relevant studies, in English language only, through systematic searches of CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO, PapersFirst, ProQuest Dissertations, and Web of Science from the inception of each database up to January 2015. An experienced medical librarian collaborated in the development of the search strategies for each electronic database. With the help of the same librarian, we divided the search results into two sets: peer-reviewed publications and potentially eligible literature. Potentially eligible literature included conference or meeting abstracts, dissertations, or registered trials that were identified through the literature searches. Table 1 details the MEDLINE search strategy, and Table 2 details the number of results from each database. To determine if complete reports of the potentially eligible literature had been published, we performed a keyword search in Google Scholar, EMBASE, and MEDLINE using the main phrases in the title combined with the authors’ names. If a full report was not identified, we used the authors’ names and the address affiliation information in the citation record to search in Google for the first and last authors’ email addresses, and, if located, we contacted authors to ask for a copy of their full report. In addition, we screened the bibliographies of all eligible studies to identify other relevant studies not captured by the database searches. Table 1. Ovid MEDLINE(R) search strategy:1"Quality of Life"/2"outcome assessment (health care)"/ or treatment outcome/ or treatment failure/3exp pain/4exp disease attributes/ or exp "signs and symptoms"/5or/1-46health status indicators/ or "severity of illness index"/ or sickness impact profile/ or interviews as topic/ or questionnaires/ or self report/7Pain Measurement/8patient satisfaction/ or patient preference/9or/6-810(quality of life or life qualit??? or hrqol or hrql).mp.11(assessment? outcome? or measure? outcome? or outcome? studies or outcome? study or outcome? assessment? or outcome? management or outcome? measure* or outcome? research or patient? outcome? or research outcome? or studies outcome? or study outcome? or therap* outcome? or treatment outcome? or treatment failure?).mp.12pain????.mp.13((activity or sever* or course) adj3 (disease or disabilit* or symptom*)).mp.14or/10-13159 or 14 [database subject headings textwords]16(questionnaire? or instrument? or interview? or inventor* or test??? or scale? or subscale? or survey? or index?? or indices or form? or score? or measurement?).mp.17(patient? rating? or subject* report? or subject* rating? or self report* or self evaluation? or self appraisal? or self assess* or self rating? or self rated).mp.18(patient? report* or patient? observ* or patient? satisf*).mp.19anchor base??.mp.20or/16-192115 and 20 [pros]22("(type 1) gaucher??" or "(type i) gaucher??" or "gaucher ?? disease (gd1)" or "gaucher ?? disease (gdi)" or "gaucher ?? disease (type 1)" or "gaucher ?? disease (type i)" or "gaucher ?? disease type 1" or "gaucher ?? disease type i" or "gaucher?? (type 1)" or "gaucher?? (type i)" or "gaucher?? disease (gd1)" or "gaucher?? disease (gdi)" or "gaucher?? type 1" or "gaucher?? type i" or "non neuronopathic gaucher??" or "noncerebral juvenile gaucher??" or "type 1 (non neuronopathic) gaucher??" or "type 1 (nonneuronopathic) gaucher??" or "type 1 gaucher??" or "type 1 gd" or "type i form GDi)" or "type 1 form GD1)" or "type i (non neuronopathic) gaucher??" or "type i (nonneuronopathic) gaucher??" or "type i gaucher??" or "type i gd").tw.2321 and 22 [pros gaucher type 1]24("(type 3) gaucher??" or "(type iii) gaucher??" or "cerebral adult form of gaucher??" or "cerebral juvenile form of gaucher??" or "chronic neuronopathic gaucher??" or "gaucher?? disease (gd3)" or "gaucher?? disease (gdiii)" or "gaucher?? disease (type 3)" or "gaucher?? disease (type iii)" or "gaucher?? disease type 3 " or "gaucher?? disease type iii" or "gaucher?? disease, subacute neuronopathic type" or "gaucher?? type 3" or "gaucher?? type iii" or "neuropathic gaucher?? disease" or "subacute neuronopathic type of gaucher??" or "type 3 chronic neuronopathic) gaucher??" or "type 3 neuronopathic) gaucher??" or "type 3 form GD3)" or "type iii form GDiii)" or "type 3 gaucher??" or "type 3 gd" or "type iii (chronic neuronopathic) gaucher??" or "type iii neuronopathic) gaucher??" or "type iii form GD3)" or "type iii gaucher??" or "type iii gd").tw.2521 and 24 [pros gaucher type 3]26fabry disease/27("alpha galactosidase a deficienc*" or "angiokeratoma? corporis diffusum" or "angiokeratoma? diffuse" or "angiokeratoma? diffusum" or "ceramide trihexosidase deficienc*" or "ceramide trihexosidosis" or "diffuse angiokeratoma?" or "fabry anderson disease" or "fabry dyslipidosis" or "fabry?? syndrome" or "fabry?? disease" or "gla deficiency" or "glycosphingolipid lipidosis" or "glycosphingolipidosis" or "glycosphingolipoidosis" or "hereditary dystopic lipidoses" or "hereditary dystopic lipidosis" or "mckusick 30150").tw.2826 or 272921 and 28 [pros Fabry]30Niemann-Pick Disease, Type B/31("b (nmpb)" or "niemann-pick a/b" or "(ndp) type b" or "b form? of niemann pick??" or "b ndp" or "b niemann pick??" or "b subtype? of niemann pick??" or "b type? of niemann pick??" or "form b of niemann pick??" or "ndp a/b" or "niemann pick (a and b)" or "niemann pick disease visceral" or "niemann pick?? (b)" or "niemann pick?? (form? b)" or "niemann pick?? (subtype? b)" or "niemann pick?? (type? b)" or "niemann pick?? a/b" or "niemann pick?? disease (b)" or "niemann pick?? disease (b form?)" or "niemann pick?? disease (b subtype?)" or "niemann pick?? disease (b type?)" or "niemann pick?? disease adult non neuronopathic" or "niemann pick?? disease adult nonneuronopathic" or "niemann pick?? disease nonneuronopathic" or "niemann pick?? disease subtype? b" or "niemann pick?? disease type a/b" or "niemann pick?? disease type b" or "niemann pick?? syndrome, type? b" or "niemann pick?? type a/b" or "niemann pick?? type? b" or "non neuronopathic niemann pick??" or "nonneurologic (type? b) forms of niemann pick??" or "nonneuronopathic niemann pick??" or "np type b" or "npa/b" or "npd type b" or "npd-a/b" or "subtype b of niemann pick??" or "type b of niemann pick??").tw.3230 or 313321 and 32 [pros Niemann-Pick B]34glycogen storage disease type ii/35("acid maltase deficienc*" or "alpha 14 glucosidase deficienc*" or "alpha-1,4-glucosidase acid deficienc*" or "alpha-1,4-glucosidase deficienc*" or "alpha-glucosidase deficienc* acid" or "cardiomuscular glycogenosis" or "deficienc* of alpha-glucosidase" or "diffuse glycogenosis" or "gaa deficienc*" or "generali?ed glycogenoses" or "generalized glycogenosis" or "glucan 1,4 alpha glucosidase deficiency syndrome" or "glycogen storage disease ii" or "glycogen storage disease type 2" or "glycogen storage disease type ii" or "glycogen storage disease,generalized" or "glycogenoses 2" or "glycogenoses generalized" or "glycogenoses ii" or "glycogenoses type 2" or "glycogenoses type ii" or "glycogenosis 2" or "glycogenosis due to acid maltase deficienc*" or "glycogenosis generalized" or "glycogenosis ii" or "glycogenosis type 2" or "glycogenosis type ii" or "gsd due to acid maltase deficienc*" or "gsd ii" or "gsd type 2" or "gsd2" or "lysosomal alpha 14 glucosidase deficiency disease" or "mckusick 23230" or pompe or "pompes disease" or "pompe's disease" or "type 2 glycogenoses" or "type 2 glycogenosis" or "type ii glycogenoses" or "type ii glycogenosis").tw.3634 or 353721 and 36 [pros Pompe]38Mucopolysaccharidosis II/39("Hunter?? disease" or "Hunter?? glossitis" or "Hunter?? hurler ?? " or "Hunter?? syndrome" or "Hurler?? Hunter?? " or "iduronate 2 sulfatase deficienc*" or "iduronate sulfatase deficienc*" or "mckusick 30990" or "mps 2" or "mps 2s" or "mps ii" or "mps iis" or "mps type 2" or "mps type 2s" or "mps type ii" or "mps type iis" or "mucopolysaccharidoses 2" or "mucopolysaccharidoses 2s" or "mucopolysaccharidoses ii" or "mucopolysaccharidoses iis" or "mucopolysaccharidoses type 2" or "mucopolysaccharidoses type 2s" or "mucopolysaccharidoses type ii" or "mucopolysaccharidoses type iis" or "mucopolysaccharidosis 2" or "mucopolysaccharidosis 2s" or "mucopolysaccharidosis ii" or "mucopolysaccharidosis iis" or "mucopolysaccharidosis type 2" or "mucopolysaccharidosis type 2s" or "mucopolysaccharidosis type ii" or "mucopolysaccharidosis type iis" or "sulfoiduronate sulfatase deficienc*" or "type 2 mucopolysaccharidoses" or "type 2 mucopolysaccharidosis" or "type 2s mucopolysaccharidoses" or "type 2s mucopolysaccharidosis" or "type ii mucopolysaccharidoses" or "type ii mucopolysaccharidosis" or "type iis mucopolysaccharidoses" or "type iis mucopolysaccharidosis").tw.4038 or 394121 and 40 [pros Mucopolysaccharidoses - MPS II Hunter Disease]42Mucopolysaccharidosis I/43("mucopolysaccharidosis type 1" or "alpha l iduronidase deficienc*" or "chondroosteodysplasia" or "chondroosteodystrophy" or "chondroosteoplasia" or "deficienc* alpha l iduronidase" or "disease hurler" or "disease hurler's" or "dysostosis multiplex" or "gargoylism" or "helmholtz harrington syndrome" or "hurler disease" or "hurler scheie syndrome" or "hurler syndrome" or "hurlers disease" or "hurler's disease" or "hurlers syndrome" or "hurler's syndrome" or "hurler scheie syndrome" or "iduronidase deficiency syndrome" or "lipochondrodystroph*" or "mckusick 25280" or "mucopolysaccharidosis 1" or "mucopolysaccharidosis 5" or "mucopolysaccharidosis i" or "mucopolysaccharidosis is" or "mucopolysaccharidosis i-sor mucopolysaccharidosis type i" or "mucopolysaccharidosis type ih" or "mucopolysaccharidosis type ih/ss" or "mucopolysaccharidosis type ihs" or "mucopolysaccharidosis type is" or "mucopolysaccharidosis v" or "pfaundler hurler syndrome" or "scheie syndrome" or "syndrome hurler's" or "syndrome hurler scheie" or "syndrome scheie" or "type ih mucopolysaccharidosis" or "type ih/ss mucopolysaccharidosis" or "type ihs mucopolysaccharidosis" or "type is mucopolysaccharidosis").tw.4442 or 434521 and 44 [pros Mucopolysaccharidoses I Hurler Disease]4623 or 25 or 29 or 33 or 37 or 41 or 45 [pros 7 rare diseases]Table 2. Results for each database searchedDatabases Searched (Platform)TOTALMEDLINE In-Process & Other Non-Indexed Citations <July 3, 2013> (Ovid)47MEDLINE(R) 1946 to Present with Daily Update <July 3, 2013> (Ovid)725Embase Classic+Embase <1947 to 2013 Week 25> (Ovid)1112PsycINFO <1806 to June Week 4 2013> (Ovid)141Cochrane Central Register of Controlled Trials <May 2013> (Ovid)25CINAHL <July 3, 2013> (EBSCO) 282(Web of Science) <July 3, 2013>Science Citation Index EPEVuZE5vdGU+PENpdGU+PEF1dGhvcj52YW4gZGVyIEJlZWs8L0F1dGhvcj48WWVhcj4yMDEyPC9Z

ZWFyPjxSZWNOdW0+MTwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3Jp

cHQiPjE8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xPC9yZWMtbnVt

YmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMHh3dHIwOXYyOXp6dmhlMDAw

N3Y5cnJqMHc1ZGR4emRyMmR0IiB0aW1lc3RhbXA9IjEzNzIzNTMyNDgiPjE8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPnZhbiBkZXIgQmVlaywgTmFkaW5lIEEuIE0uIEUu

PC9hdXRob3I+PGF1dGhvcj5kZSBWcmllcywgSnVuYSBNLjwvYXV0aG9yPjxhdXRob3I+SGFnZW1h

bnMsIE1hcmxvZXMgTC4gQy48L2F1dGhvcj48YXV0aG9yPkhvcCwgV2ltIEMuIEouPC9hdXRob3I+

PGF1dGhvcj5Lcm9vcywgTWFyaWFuIEEuPC9hdXRob3I+PGF1dGhvcj5Xb2trZSwgSm9obiBILiBK

LjwvYXV0aG9yPjxhdXRob3I+ZGUgVmlzc2VyLCBNYXJpYW5uZTwvYXV0aG9yPjxhdXRob3I+dmFu

IEVuZ2VsZW4sIEJhemllbCBHLiBNLjwvYXV0aG9yPjxhdXRob3I+S3VrcywgSmFuIEIuIE0uPC9h

dXRob3I+PGF1dGhvcj52YW4gZGVyIEtvb2ksIEFubmVrZSBKLjwvYXV0aG9yPjxhdXRob3I+Tm90

ZXJtYW5zLCBOaWNvbGV0dGUgQy48L2F1dGhvcj48YXV0aG9yPkZhYmVyLCBLYXJpbiBHLjwvYXV0

aG9yPjxhdXRob3I+VmVyc2NodXVyZW4sIEphbiBKLiBHLiBNLjwvYXV0aG9yPjxhdXRob3I+UmV1

c2VyLCBBcm5vbGQgSi4gSi48L2F1dGhvcj48YXV0aG9yPnZhbiBkZXIgUGxvZWcsIEFucyBULjwv

YXV0aG9yPjxhdXRob3I+dmFuIERvb3JuLCBQaWV0ZXIgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9j

b250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIE5ldXJvbG9neSwgQ2VudGVy

IGZvciBMeXNvc29tYWwgYW5kIE1ldGFib2xpYyBEaXNlYXNlcywgRXJhc211cyBNQyBVbml2ZXJz

aXR5IE1lZGljYWwgQ2VudGVyLCAmYXBvcztzLUdyYXZlbmRpamt3YWwgMjMwLCAzMDE1IENFLCBS

b3R0ZXJkYW0sIHRoZSBOZXRoZXJsYW5kcy4gbi5iZWVrQGVyYXNtdXNtYy5ubC48L2F1dGgtYWRk

cmVzcz48dGl0bGVzPjx0aXRsZT5DbGluaWNhbCBmZWF0dXJlcyBhbmQgcHJlZGljdG9ycyBmb3Ig

ZGlzZWFzZSBuYXR1cmFsIHByb2dyZXNzaW9uIGluIGFkdWx0cyB3aXRoIFBvbXBlIGRpc2Vhc2U6

IGEgbmF0aW9ud2lkZSBwcm9zcGVjdGl2ZSBvYnNlcnZhdGlvbmFsIHN0dWR5PC90aXRsZT48c2Vj

b25kYXJ5LXRpdGxlPk9ycGhhbmV0IEpvdXJuYWwgT2YgUmFyZSBEaXNlYXNlczwvc2Vjb25kYXJ5

LXRpdGxlPjxhbHQtdGl0bGU+T3JwaGFuZXQgSiBSYXJlIERpczwvYWx0LXRpdGxlPjwvdGl0bGVz

PjxwYWdlcz44ODwvcGFnZXM+PHZvbHVtZT43PC92b2x1bWU+PGtleXdvcmRzPjxrZXl3b3JkPkFk

dWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+RGlzZWFzZSBQcm9n

cmVzc2lvbjwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2x5Y29n

ZW4gU3RvcmFnZSBEaXNlYXNlL2RpIFtEaWFnbm9zaXNdPC9rZXl3b3JkPjxrZXl3b3JkPkdseWNv

Z2VuIFN0b3JhZ2UgRGlzZWFzZS9lbiBbRW56eW1vbG9neV08L2tleXdvcmQ+PGtleXdvcmQ+R2x5

Y29nZW4gU3RvcmFnZSBEaXNlYXNlL3BhIFtQYXRob2xvZ3ldPC9rZXl3b3JkPjxrZXl3b3JkPipH

bHljb2dlbiBTdG9yYWdlIERpc2Vhc2UgVHlwZSBJSS9kaSBbRGlhZ25vc2lzXTwva2V5d29yZD48

a2V5d29yZD5HbHljb2dlbiBTdG9yYWdlIERpc2Vhc2UgVHlwZSBJSS9lbiBbRW56eW1vbG9neV08

L2tleXdvcmQ+PGtleXdvcmQ+R2x5Y29nZW4gU3RvcmFnZSBEaXNlYXNlIFR5cGUgSUkvcGEgW1Bh

dGhvbG9neV08L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8

L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3Rp

dmUgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5hbHBoYS1HbHVjb3NpZGFzZXMvZ2UgW0dlbmV0

aWNzXTwva2V5d29yZD48a2V5d29yZD5hbHBoYS1HbHVjb3NpZGFzZXMvbWUgW01ldGFib2xpc21d

PC9rZXl3b3JkPjxrZXl3b3JkPkVDIDMtMi0xLTIwIChHQUEgcHJvdGVpbiwgaHVtYW4pPC9rZXl3

b3JkPjxrZXl3b3JkPkVDIDMtMi0xLTIwIChhbHBoYS1HbHVjb3NpZGFzZXMpPC9rZXl3b3JkPjwv

a2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTI8L3llYXI+PC9kYXRlcz48aXNibj4xNzUwLTExNzI8

L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjMxNDcyMjg8L2FjY2Vzc2lvbi1udW0+PGxhYmVsPkFydGlj

bGVfTUVETElORTwvbGFiZWw+PHdvcmstdHlwZT5SZXNlYXJjaCBTdXBwb3J0LCBOb24tVS5TLiBH

b3YmYXBvczt0PC93b3JrLXR5cGU+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly9vdmlk

c3Aub3ZpZC5jb20vb3ZpZHdlYi5jZ2k/VD1KUyZhbXA7Q1NDPVkmYW1wO05FV1M9TiZhbXA7UEFH

RT1mdWxsdGV4dCZhbXA7RD1tZXN4JmFtcDtBTj0yMzE0NzIyODwvdXJsPjwvcmVsYXRlZC11cmxz

PjwvdXJscz48Y3VzdG9tMj5QTUMzNTUxNzE5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNl

LW51bT5odHRwOi8vZHguZG9pLm9yZy8xMC4xMTg2LzE3NTAtMTE3Mi03LTg4PC9lbGVjdHJvbmlj

LXJlc291cmNlLW51bT48cmVtb3RlLWRhdGFiYXNlLW5hbWU+TUVETElORTwvcmVtb3RlLWRhdGFi

YXNlLW5hbWU+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5PdmlkIFRlY2hub2xvZ2llczwvcmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5FbmdsaXNoPC9sYW5ndWFnZT48L3JlY29y

ZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj52YW4gZGVyIEJlZWs8L0F1dGhvcj48WWVhcj4yMDEyPC9Z

ZWFyPjxSZWNOdW0+MTwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3Jp

cHQiPjE8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xPC9yZWMtbnVt

YmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMHh3dHIwOXYyOXp6dmhlMDAw

N3Y5cnJqMHc1ZGR4emRyMmR0IiB0aW1lc3RhbXA9IjEzNzIzNTMyNDgiPjE8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPnZhbiBkZXIgQmVlaywgTmFkaW5lIEEuIE0uIEUu

PC9hdXRob3I+PGF1dGhvcj5kZSBWcmllcywgSnVuYSBNLjwvYXV0aG9yPjxhdXRob3I+SGFnZW1h

bnMsIE1hcmxvZXMgTC4gQy48L2F1dGhvcj48YXV0aG9yPkhvcCwgV2ltIEMuIEouPC9hdXRob3I+

PGF1dGhvcj5Lcm9vcywgTWFyaWFuIEEuPC9hdXRob3I+PGF1dGhvcj5Xb2trZSwgSm9obiBILiBK

LjwvYXV0aG9yPjxhdXRob3I+ZGUgVmlzc2VyLCBNYXJpYW5uZTwvYXV0aG9yPjxhdXRob3I+dmFu

IEVuZ2VsZW4sIEJhemllbCBHLiBNLjwvYXV0aG9yPjxhdXRob3I+S3VrcywgSmFuIEIuIE0uPC9h

dXRob3I+PGF1dGhvcj52YW4gZGVyIEtvb2ksIEFubmVrZSBKLjwvYXV0aG9yPjxhdXRob3I+Tm90

ZXJtYW5zLCBOaWNvbGV0dGUgQy48L2F1dGhvcj48YXV0aG9yPkZhYmVyLCBLYXJpbiBHLjwvYXV0

aG9yPjxhdXRob3I+VmVyc2NodXVyZW4sIEphbiBKLiBHLiBNLjwvYXV0aG9yPjxhdXRob3I+UmV1

c2VyLCBBcm5vbGQgSi4gSi48L2F1dGhvcj48YXV0aG9yPnZhbiBkZXIgUGxvZWcsIEFucyBULjwv

YXV0aG9yPjxhdXRob3I+dmFuIERvb3JuLCBQaWV0ZXIgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9j

b250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIE5ldXJvbG9neSwgQ2VudGVy

IGZvciBMeXNvc29tYWwgYW5kIE1ldGFib2xpYyBEaXNlYXNlcywgRXJhc211cyBNQyBVbml2ZXJz

aXR5IE1lZGljYWwgQ2VudGVyLCAmYXBvcztzLUdyYXZlbmRpamt3YWwgMjMwLCAzMDE1IENFLCBS

b3R0ZXJkYW0sIHRoZSBOZXRoZXJsYW5kcy4gbi5iZWVrQGVyYXNtdXNtYy5ubC48L2F1dGgtYWRk

cmVzcz48dGl0bGVzPjx0aXRsZT5DbGluaWNhbCBmZWF0dXJlcyBhbmQgcHJlZGljdG9ycyBmb3Ig

ZGlzZWFzZSBuYXR1cmFsIHByb2dyZXNzaW9uIGluIGFkdWx0cyB3aXRoIFBvbXBlIGRpc2Vhc2U6

IGEgbmF0aW9ud2lkZSBwcm9zcGVjdGl2ZSBvYnNlcnZhdGlvbmFsIHN0dWR5PC90aXRsZT48c2Vj

b25kYXJ5LXRpdGxlPk9ycGhhbmV0IEpvdXJuYWwgT2YgUmFyZSBEaXNlYXNlczwvc2Vjb25kYXJ5

LXRpdGxlPjxhbHQtdGl0bGU+T3JwaGFuZXQgSiBSYXJlIERpczwvYWx0LXRpdGxlPjwvdGl0bGVz

PjxwYWdlcz44ODwvcGFnZXM+PHZvbHVtZT43PC92b2x1bWU+PGtleXdvcmRzPjxrZXl3b3JkPkFk

dWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+RGlzZWFzZSBQcm9n

cmVzc2lvbjwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2x5Y29n

ZW4gU3RvcmFnZSBEaXNlYXNlL2RpIFtEaWFnbm9zaXNdPC9rZXl3b3JkPjxrZXl3b3JkPkdseWNv

Z2VuIFN0b3JhZ2UgRGlzZWFzZS9lbiBbRW56eW1vbG9neV08L2tleXdvcmQ+PGtleXdvcmQ+R2x5

Y29nZW4gU3RvcmFnZSBEaXNlYXNlL3BhIFtQYXRob2xvZ3ldPC9rZXl3b3JkPjxrZXl3b3JkPipH

bHljb2dlbiBTdG9yYWdlIERpc2Vhc2UgVHlwZSBJSS9kaSBbRGlhZ25vc2lzXTwva2V5d29yZD48

a2V5d29yZD5HbHljb2dlbiBTdG9yYWdlIERpc2Vhc2UgVHlwZSBJSS9lbiBbRW56eW1vbG9neV08

L2tleXdvcmQ+PGtleXdvcmQ+R2x5Y29nZW4gU3RvcmFnZSBEaXNlYXNlIFR5cGUgSUkvcGEgW1Bh

dGhvbG9neV08L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8

L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3Rp

dmUgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5hbHBoYS1HbHVjb3NpZGFzZXMvZ2UgW0dlbmV0

aWNzXTwva2V5d29yZD48a2V5d29yZD5hbHBoYS1HbHVjb3NpZGFzZXMvbWUgW01ldGFib2xpc21d

PC9rZXl3b3JkPjxrZXl3b3JkPkVDIDMtMi0xLTIwIChHQUEgcHJvdGVpbiwgaHVtYW4pPC9rZXl3

b3JkPjxrZXl3b3JkPkVDIDMtMi0xLTIwIChhbHBoYS1HbHVjb3NpZGFzZXMpPC9rZXl3b3JkPjwv

a2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTI8L3llYXI+PC9kYXRlcz48aXNibj4xNzUwLTExNzI8

L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjMxNDcyMjg8L2FjY2Vzc2lvbi1udW0+PGxhYmVsPkFydGlj

bGVfTUVETElORTwvbGFiZWw+PHdvcmstdHlwZT5SZXNlYXJjaCBTdXBwb3J0LCBOb24tVS5TLiBH

b3YmYXBvczt0PC93b3JrLXR5cGU+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly9vdmlk

c3Aub3ZpZC5jb20vb3ZpZHdlYi5jZ2k/VD1KUyZhbXA7Q1NDPVkmYW1wO05FV1M9TiZhbXA7UEFH

RT1mdWxsdGV4dCZhbXA7RD1tZXN4JmFtcDtBTj0yMzE0NzIyODwvdXJsPjwvcmVsYXRlZC11cmxz

PjwvdXJscz48Y3VzdG9tMj5QTUMzNTUxNzE5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNl

LW51bT5odHRwOi8vZHguZG9pLm9yZy8xMC4xMTg2LzE3NTAtMTE3Mi03LTg4PC9lbGVjdHJvbmlj

LXJlc291cmNlLW51bT48cmVtb3RlLWRhdGFiYXNlLW5hbWU+TUVETElORTwvcmVtb3RlLWRhdGFi

YXNlLW5hbWU+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5PdmlkIFRlY2hub2xvZ2llczwvcmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5FbmdsaXNoPC9sYW5ndWFnZT48L3JlY29y

ZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA 1xpanded (SCI-EXPANDED) -1900-presentSocial Sciences Citation Index (SSCI)-1956-presentConference Proceedings Citation Index- Science(CPCI-S) 1990-presentConference Proceedings Citation Index- Social Science & Humanities (CPCI-SSH)-1990-present1392PapersFirst <July 3, 2013> (ProQuest)8Dissertations & Theses <July 3, 2013> (ProQuest)12TOTAL =SUM(ABOVE) \# "0" 3744 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download